Hematological Disorders Market, By Diagnostic Test (Flow Cytometry, Complete Blood Count, Immunohistochemistry, Molecular Diagnostics, Bone Marrow Aspiration and Biopsy and Cytogenetics), By Therapeutic Approach, By Disease Type, By Disease Category, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV5979
|
Published Date
September 2026
|
Pages
355
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Hematological Disorders Market size was valued at US$ 138,700.5 Million in 2025, expanding at a CAGR of 8.2% from 2026 to 2033.
Hematological diseases include malignant and non-malignant diseases of blood cells, bone marrow, lymphoid tissues, and associated immune systems; in the commercial space, the diagnosis and treatment are a combination of laboratory diagnostics and very specialized therapeutic areas. The diagnostics segment encompasses routine hematology along with flow cytometry, immunohistochemistry, molecular tests, cytogenetic tests, and bone marrow studies to diagnose diseases, their subtypes, prognosis, and residual disease status. The corresponding therapy segment includes targeted drugs, chemotherapy, transplantation, radiotherapy, and immunotherapy. The extent of specialty can be seen in the EBMT Registry, which registered 37,329 new cases in 2025, comprising 18,875 allogeneic HCTs and 18,504 autologous HCTs. This positions the market around increasingly integrated diagnosis-to-treatment pathways rather than isolated products.
Hematological Disorders Market- Market Dynamics
Expansion of Molecularly Defined and Treatment-Responsive Disease Classification
Targeted therapies are redefining the needs that clinicians have regarding hematological diagnostics: the sole identification of the disease itself is no longer sufficient in cases where molecular changes, immunophenotype, and eligibility for treatment play an important role in the choice of treatment method. This is especially noticeable in the treatment pathways for lymphomas and leukemias, where diagnostics include morphology, flow cytometry, cytogenetics, and molecular tests. In 2025, the FDA granted traditional approval for acalabrutinib in newly diagnosed mantle cell lymphoma based on results from the 598 patients\' ECHO trial, as well as an expanded treatment indication for acalabrutinib. These types of regulations emphasize the link between disease classification and targeted treatment. Diagnostic labs are thus under increasing pressure to provide timely, standardized, and actionable information about diseases in order to facilitate targeted treatment.
Hematological Disorders Market- Segmentation Analysis:
The Global Hematological Disorders Market is segmented on the basis of Diagnostic Test, Therapeutic Approach, Disease Type, Disease Category, and Region.
By diagnostic test, the test structure for diagnostic tests follows a hierarchy of hematopathology tests rather than tests that could be substituted. Complete blood counts provide a quantitative assessment of blood cell disorders, while bone marrow aspiration and biopsy give cellular and architectural proof, and flow cytometry offers multi-parameter immunophenotyping. Immunohistochemistry reveals marker patterns on tissues, while molecular diagnostics and cytogenetics help identify genetic and chromosomal disorders. The technology differentiation is evident in flow cytometry, in which the 2025 CytoFLEX mosaic module by Beckman Coulter enables 88 detection channels. This demonstrates how the industry is shifting towards high-dimensional assessment. The commercial importance of the above segmentation, therefore, arises from the complementary diagnostic depth.
By therapeutic approach, the therapeutic strategy is dictated by disease biology, patient eligibility, disease stage, prior treatment exposure, and response durability, rather than by a simple hierarchy of therapies. Chemotherapy and radiation are part of established treatment pathways, while targeted therapy and immunotherapy increasingly take advantage of molecular or immune features. Stem cell transplantation remains an intensive option for appropriately selected patients, while other approaches are available for disease-specific or supportive needs. The change is reflected in 2025 regulatory evidence: FDA approval of tafasitamab with lenalidomide and rituximab for relapsed or refractory follicular lymphoma was based on the inMIND trial with 548 patients, demonstrating the integration of combination immunotherapy into treatment strategies, rather than as a stand-alone modality. Thus, therapeutic segmentation increasingly reflects individualized treatment sequencing.
Hematological Disorders Market- Geographical Insights
Europe occupies a position where hematological treatment is supported by a well-established transplantation, registry, and specialist-center ecosystem. The EBMT\'s 2025 registry recorded 18,875 allogeneic hematopoietic cell transplants and 18,504 autologous transplants alongside 4,757 CAR T procedures, showing the wide reach of advanced cellular treatment infrastructure across the region\'s clinical network. This ecosystem also creates a need for diagnostic monitoring because transplantation and cellular therapies require disease characterization before treatment and monitoring afterward. EBMT achieved ISO/IEC 27001:2022 certification for its registry in October 2025, demonstrating the growing importance of clinical data environments. Europe, therefore, represents a connected market where diagnostics, transplantation, cellular therapy, and clinical data infrastructure increasingly overlap.
Asia is significant market due to burden of hematological diseases and expanding specialist treatment infrastructure, with China playing a key role in advanced cellular therapy. A 2025 Chinese expert consensus emphasizes flow cytometry\'s role in diagnosing, classifying, treating, and monitoring malignancies. The region is also building treatment infrastructure: Shanghai SinoUnited Hospital opened an international CAR T cell therapy center on May 21, 2025, aimed at hematological cancers and patients from other countries. These developments show that Asian markets are moving beyond hematology services toward specialized molecular, cellular, and immunotherapy capabilities, broadening the diagnostic and therapeutic infrastructure needed for complex blood disorders.
Hematological Disorders Market- Competitive Landscape:
Competition is now defined by the capacity to link deep diagnostic testing with clinical workflow processes rather than by the supply of single instrumentation or therapy. In diagnostics, firms such as Beckman Coulter, BD, Roche, Abbott, Thermo Fisher Scientific, and other specialized suppliers have been competing based on multiparametric testing, automation, reagent systems, molecular technologies, and laboratory integration. The launch of the CytoFLEX mosaic spectral module by Beckman Coulter by 2025, featuring ten autofluorescence channels along with an advanced detection system, shows how instrument manufacturers can differentiate themselves through complex sample handling and analysis. Therapies, drug firms, and biotechs are now competing in terms of specific inhibitors, antibody combinations, CAR-T therapy, and clinical data based on the condition being addressed. Thus, the competitive landscape is moving towards integrated precision care capabilities and clinically proven differentiation.
Recent Developments:
- In December 2025, pirtobrutinib was FDA approved under the traditional route for treating CLL/SLL, which is relapsed or refractory post-covalent BTK inhibitor use. The study used for FDA approval was BRUIN-CLL-321, where the randomization of the patients was made for 238, and pirtobrutinib had a median PFS of 11.2 months.
- In December 2025, lisocabtagene maraleucel (Breyanzi) was FDA approved for treating adults with relapsed or refractory marginal zone lymphoma post second-line systemic therapy. The efficacy analysis for FDA approval involved 77 patients who underwent leukapheresis and had an 84.4% response rate.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL HEMATOLOGICAL DISORDERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- Amgen Inc.
- Sanofi
- Baxter International Inc.
- Bayer AG
- Bristol Myers Squibb
- Hoffmann-La Roche Ltd.
- Biogen Inc.
- Novartis AG
- Pfizer Inc.
- GSK plc
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
- Sysmex Corporation
- Siemens Healthineers
- AstraZeneca
- AbbVie Inc.
- CSL Behring
- Novo Nordisk A/S
- Vertex Pharmaceuticals
- Sobi
- Others
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DIAGNOSTIC TEST- MARKET ANALYSIS, 2020 - 2033
- Flow Cytometry
- Complete Blood Count
- Immunohistochemistry
- Molecular Diagnostics
- Bone Marrow Aspiration and Biopsy
- Cytogenetics
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY THERAPEUTIC APPROACH- MARKET ANALYSIS, 2020 - 2033
- Targeted Therapy
- Chemotherapy
- Stem Cell Transplant
- Radiation Therapy
- Immunotherapy
- Others
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2020 - 2033
- Leukemia
- Lymphoma
- Multiple Myeloma
- Anemia
- Hemophilia & Other Bleeding Disorders
- Sickle Cell Disease & Other Hemoglobinopathies
- Thrombosis & Other Coagulation Disorders
- Myelodysplastic & Myeloproliferative Disorders
- Others
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DISEASE CATEGORY- MARKET ANALYSIS, 2020 - 2033
- Malignant Hematological Disorders
- Non-Malignant Hematological Disorders
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Hematological Disorders Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.2. Competitive Insights
3. Hematological Disorders Key Market Trends
3.1. Hematological Disorders Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Hematological Disorders Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Hematological Disorders Market Opportunities
3.4. Hematological Disorders Market Future Trends
4. Hematological Disorders Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Hematological Disorders Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Hematological Disorders Market Landscape
6.1. Hematological Disorders Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Hematological Disorders Market – By Diagnostic Test
7.1. Overview
7.1.1. Segment Share Analysis, By Diagnostic Test, 2025 & 2033 (%)
7.1.2. Flow Cytometry
7.1.3. Complete Blood Count
7.1.4. Immunohistochemistry
7.1.5. Molecular Diagnostics
7.1.6. Bone Marrow Aspiration and Biopsy
7.1.7. Cytogenetics
8. Hematological Disorders Market – By Therapeutic Approach
8.1. Overview
8.1.1. Segment Share Analysis, By Therapeutic Approach, 2025 & 2033 (%)
8.1.2. Targeted Therapy
8.1.3. Chemotherapy
8.1.4. Stem Cell Transplant
8.1.5. Radiation Therapy
8.1.6. Immunotherapy
8.1.7. Others
9. Hematological Disorders Market – By Disease Type
9.1. Overview
9.1.1. Segment Share Analysis, By Disease Type, 2025 & 2033 (%)
9.1.2. Leukemia
9.1.3. Lymphoma
9.1.4. Multiple Myeloma
9.1.5. Anemia
9.1.6. Hemophilia & Other Bleeding Disorders
9.1.7. Sickle Cell Disease & Other Hemoglobinopathies
9.1.8. Thrombosis & Other Coagulation Disorders
9.1.9. Myelodysplastic & Myeloproliferative Disorders
9.1.10. Others
10. Hematological Disorders Market – By Disease Category
10.1. Overview
10.1.1. Segment Share Analysis, By Disease Category, 2025 & 2033 (%)
10.1.2. Malignant Hematological Disorders
10.1.3. Non-Malignant Hematological Disorders
11. Hematological Disorders Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Hematological Disorders Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Hematological Disorders Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.17. Denmark
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Poland Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.17.4. Denmark Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.17.5. Denmark Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.17.6. Denmark Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.3.18. Rest of Europe
11.3.18.1. Overview
11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.18.3. Rest of the Europe Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.3.18.5. Rest of the Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Hematological Disorders Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.16. Taiwan
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Taiwan Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.16.4. Taiwan Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.16.5. Taiwan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.16.6. Taiwan Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.17. Vietnam
11.4.17.1. Overview
11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.17.3. Vietnam Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.17.4. Vietnam Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.17.5. Vietnam Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.17.6. Vietnam Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.4.18. Rest of APAC
11.4.18.1. Overview
11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.18.3. Rest of APAC Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.4.18.4. Rest of APAC Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.4.18.5. Rest of APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.4.18.6. Rest of APAC Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Hematological Disorders Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Hematological Disorders Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.14. Iran
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Iran Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.14.4. Iran Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.14.5. Iran Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.14.6. Iran Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.15. Qatar
11.6.15.1. Overview
11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.15.3. Qatar Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.15.4. Qatar Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.15.5. Qatar Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.15.6. Qatar Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
11.6.16. Rest of MEA
11.6.16.1. Overview
11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.16.3. Rest of MEA Market Size and Forecast, By Diagnostic Test, 2020 - 2033 (US$ Million)
11.6.16.4. Rest of MEA Market Size and Forecast, By Therapeutic Approach, 2020 - 2033 (US$ Million)
11.6.16.5. Rest of MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
11.6.16.6. Rest of MEA Market Size and Forecast, By Disease Category, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Hematological Disorders Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Abbott Laboratories
12.2.2. Amgen Inc.
12.2.3. Sanofi
12.2.4. Baxter International Inc.
12.2.5. Bayer AG
12.2.6. Bristol Myers Squibb
12.2.7. F. Hoffmann-La Roche Ltd.
12.2.8. Biogen Inc.
12.2.9. Novartis AG
12.2.10. Pfizer Inc.
12.2.11. GSK plc
12.2.12. Johnson & Johnson
12.2.13. Takeda Pharmaceutical Company Limited
12.2.14. Sysmex Corporation
12.2.15. Siemens Healthineers
12.2.16. AstraZeneca
12.2.17. AbbVie Inc.
12.2.18. CSL Behring
12.2.19. Novo Nordisk A/S
12.2.20. Vertex Pharmaceuticals
12.2.21. Sobi
12.2.22. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL HEMATOLOGICAL DISORDERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- Amgen Inc.
- Sanofi
- Baxter International Inc.
- Bayer AG
- Bristol Myers Squibb
- Hoffmann-La Roche Ltd.
- Biogen Inc.
- Novartis AG
- Pfizer Inc.
- GSK plc
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
- Sysmex Corporation
- Siemens Healthineers
- AstraZeneca
- AbbVie Inc.
- CSL Behring
- Novo Nordisk A/S
- Vertex Pharmaceuticals
- Sobi
- Others
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DIAGNOSTIC TEST- MARKET ANALYSIS, 2020 - 2033
- Flow Cytometry
- Complete Blood Count
- Immunohistochemistry
- Molecular Diagnostics
- Bone Marrow Aspiration and Biopsy
- Cytogenetics
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY THERAPEUTIC APPROACH- MARKET ANALYSIS, 2020 - 2033
- Targeted Therapy
- Chemotherapy
- Stem Cell Transplant
- Radiation Therapy
- Immunotherapy
- Others
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2020 - 2033
- Leukemia
- Lymphoma
- Multiple Myeloma
- Anemia
- Hemophilia & Other Bleeding Disorders
- Sickle Cell Disease & Other Hemoglobinopathies
- Thrombosis & Other Coagulation Disorders
- Myelodysplastic & Myeloproliferative Disorders
- Others
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY DISEASE CATEGORY- MARKET ANALYSIS, 2020 - 2033
- Malignant Hematological Disorders
- Non-Malignant Hematological Disorders
GLOBAL HEMATOLOGICAL DISORDERS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
